TC
IOVA icon

TwinBeech Capital’s Iovance Biotherapeutics IOVA Stock Holding History

TwinBeech Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,077
Closed -$298K – 661
2024
Q1 		$298K Buy
+20,077
New +$234K 0.01% 484
2022
Q4 		– Sell
-128,269
Closed -$1.23M – 798
2022
Q3 		$1.23M Buy
+128,269
New +$1.48M 0.03% 418

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

TwinBeech Capital's IOVA Position: Q2 2024 in Review

TwinBeech Capital sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 20,077 shares — an estimated $298K sold.

TwinBeech Capital first reported a position in IOVA in Q3 2022 and held it in 2 quarters. The position peaked at $1.23M in Q3 2022. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • TwinBeech Capital reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • TwinBeech Capital sold 20,077 Iovance Biotherapeutics shares in Q2 2024, an estimated $298K.
  • TwinBeech Capital first reported a position in Iovance Biotherapeutics in Q3 2022 and held it in 2 quarters.
  • TwinBeech Capital's Iovance Biotherapeutics position peaked at $1.23M in Q3 2022.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on TwinBeech Capital's 13F filing for Q2 2024, filed 14 Aug 2024.